Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

atezolizumab 3cediranib 2Specimen Handling 2selinexor 1sargramostim 1romidepsin 1pazopanib 1cabozantinib 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Warfarin 1Vitamin B 6 1Thyroxine 1Temozolomide 1Sunitinib 1Radiotherapy 1Radiation 1Pyridoxine 1Promethazine 1Prochlorperazine 1Petrolatum 1Lorazepam 1Loperamide 1Immunoglobulin G 1Ifosfamide 1HhAntag691 1Flurazepam 1Filgrastim 1Estazolam 1Doxorubicin 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma, Alveolar Soft Part × Diphenoxylate × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡